genomics

Genomics appoints Sekar Kathiresan as scientific advisory board chair

pharmafile | January 11, 2016 | Appointment | Sales and Marketing genomics 

Genomics has appointed Dr Sekar Kathiresan as chair of the company’s newly-formed scientific advisory board as chair, with immediate effect. 

Dr Kathiresan is one of the world leaders in the genetics of heart disease. He is the director of preventive cardiology at Massachusetts General Hospital (MGH), an associate member in the Broad Institute’s program in medical and population genetics, and an associate professor of medicine at Harvard Medical School. He received his M.D. from Harvard Medical School in 1997. 

Sekar completed his clinical training in internal medicine and cardiology at MGH and served as chief resident in internal medicine at MGH in 2002-2003. In 2008, he joined the research faculties of the MGH Cardiovascular Research Center and the MGH Center for Human Genetic Research.

In 2015 Sekar was selected by the National Institutes of Health to join a panel of experts formed to steer President Obama’s Precision Medicine Initiative.

On his appointment, Kathiresan says: “Genomics plc is dedicated, as am I, to making sense of the explosion in genomic data to improve patient care. The company has developed a unique analytical platform for genomic data analysis and interpretation, and I am excited to be joining.  I look forward to working with the team to help guide the next stage in the company’s development.”

While John Colenutt, chief executive says: “I would like to welcome Sek. We have established the SAB to support the company in achieving its ambitions as a leading analysis company in the genomics space.

“We are delighted to be working with such a highly-regarded and world-renowned human geneticist. I am confident that Sek’s experience and knowledge will prove a tremendous asset as Genomics plc gains momentum and continues to grow – his appointment as chair demonstrates our commitment to being a global leader in the field of genomics.”

Related Content

genes

AstraZeneca’s Alexion partners with Pfizer for rare disease therapies

Alexion, AstraZeneca’s Rare Disease division, has announced that it has entered a definitive purchase and …

citylabs-banner

Manchester emerges as genomics research hub

­­Manchester, UK is emerging as a major hub for genomics research, according to a new …

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

The US Department of Justice has launched an investigation into the sales and marketing practices …

Latest content